News Center

Home page

Peak Report

News reports

Azithromycin Sulfate for Injection Instructions

Release time:

2020-07-31

Approval Date: March 29, 2007
First Amendment Date: November 13, 2007
Second Amendment Date: October 31, 2014

-dimensional Ruth
Azithromycin Sulfate Instructions
Please read the instructions carefully and use them under the guidance of doctors.

[Drug Name]
Common Name: Azithromycin Sulfate for Injection
Trade Name: Verude
English Name: Azithromycin Sulfate for Injection
Chinese Pinyin: ZhusheyongLiusuan Aqimeisu
[Ingredients] The main ingredient of this product is azithromycin sulfate, and its chemical name is: 9-deoxy -9 α-aza -9 α-methyl -9 α-erythromycin A sulfate.
Chemical Structural Formula:

Molecular Formula: C38H72N2012 H2S04
Molecular Weight: 847.00
[Character] This product is white or almost white loose block or powder.
[indications] 1, for acute pharyngitis caused by Streptococcus pyogenes, acute tonsillitis.
2. For pneumonia caused by Streptococcus pneumoniae, influenza bacillus and Mycoplasma pneumoniae.
3, for chlamydia caused by urethritis and cervicitis.
4. It is used for acute bronchitis and acute attack of chronic bronchitis caused by sensitive bacteria.
5. For skin and soft tissue infections caused by sensitive bacteria.
[Specifications] 0.25g (250000 units) and 0.5g (500000 units) (calculated by C38H72N2012)

[Usage and Dosage] Fully dissolve the product with appropriate amount of water for injection to prepare a solution containing 0.1g per 1ml, then add it to 250ml or 500ml of 0.9 sodium chloride injection or 5% glucose injection, and the final azithromycin concentration is 1.0-2.0 mg/ml for intravenous drip, instillation time: 1 mg/ml, instillation for 3 hours; 2 mg/ml, instillation for 1 hour. For the treatment of community-acquired pneumonia, the adult dosage is 0.5g each time, once a day, for at least 2 consecutive days. Next, azithromycin oral preparation 0.5g/day, 7-10 days of treatment for a course of treatment. The timing of conversion to oral therapy should be determined by the physician based on clinical response. For the treatment of pelvic inflammatory disease, the adult dosage is 0.5g each time, once a day. After 1 day or 2 days of medication, azithromycin oral preparation O.25g is used instead, with 7 days as a course of treatment. The timing of conversion to oral therapy should be determined by the physician based on clinical response. If an anaerobic infection is suspected, an anti-anaerobic drug should be used.
[adverse reactions] occasionally can appear dizziness, headache and fever, rash, joint pain and other allergic reactions, rare anaphylactic shock and angioedema. A few patients may have transient neutropenia and elevated serum aminotransferase.
[taboo] to erythromycin or other macrolide drug allergy is prohibited.
[Precautions] Patients with liver damage should use this product with caution.
[medication for pregnant and lactating women] animal experiments have shown that azithromycin has no effect on the fetus, but it is still lack of experience in the application of human pregnant women, so it is necessary to fully weigh the pros and cons in the application of pregnant women.
There is no information on whether azithromycin can be secreted into breast milk, and the use of azithromycin in lactating women should be considered with caution.
[Children's medication] The dosage and administration method for children under 6 months of age have not been established. Efficacy and safety for the treatment of otitis media in infants less than 6 months of age, community-acquired pneumonia, and pharyngitis or tonsillitis in children less than 2 years of age have not been established.
[Geriatric use] This experiment has not been performed and there are no reliable references.
[Drug Interactions] l. When combined with aminophylline, attention should be paid to monitoring the blood concentration of the latter.
2, and warfarin should pay attention to check the prothrombin time.
3, combined with carbamazepine and digoxin, can increase the blood concentration of carbamazepine and digoxin.
[Overdose] This experiment was not performed and there are no reliable references.
[Pharmacology and Toxicology] Azithromycin is a 15-member ring macrolide, the first variety of nitrogen lactones. Its mechanism of action is the same as that of erythromycin, which mainly binds to the 50s subunit of bacterial ribosome and inhibits RNA-dependent protein synthesis. This product has good antibacterial effect on Streptococcus pyogenes, Streptococcus pneumoniae and influenza bacillus, and also has antibacterial activity on Staphylococcus. This product on Staphylococcus, Streptococcus and other Gram-positive cocci antibacterial effect is slightly worse than erythromycin on influenza bacilli and Moraxella catarrh antibacterial effect than erythromycin 4~8 times and 2~4 times, on a small number of Escherichia coli, Salmonella, Shigella can also have antibacterial effect. This product has good antimicrobial effect on anaerobic bacteria such as digestive streptococcus, mycoplasma pneumoniae and chlamydia trachomatis.
[Pharmacokinetics] This product is widely distributed in the body, and its concentration in various tissues can reach l0 ~ 100 times of the blood drug concentration in the same period. This product has high concentration in macrophages and fibroblasts, the former can transport azithromycin to the site of inflammation. The half-life (tl/2) of azithromycin after a single dose is 35-48 hours, more than 50% of the dose is excreted through the biliary tract in the original form, and about 4.5 within 72 hours after administration is excreted in the original form with urine.
[Storage] Closed and stored in a cool place (not more than 20 ℃).
[Packaging] Glass bottles, 0.25g × 2 bottles/box, 0.25g × 1 bottle/box, 0.25g × 10 bottles/box, 0.5g × 1 bottle/box, 0.5g × 10 bottles/box.
[validity] tentatively 24 months.
[Implementation Standard] WS-359(X-305)-2002(1)(0.25g);WS-359(X-305)-2002(2)(0.5g)
[Approval Document No.] H20000728(0.25g), H20000729(0.5g).
[Production Enterprise]
Enterprise Name: Zhejiang Jianfeng Pharmaceutical Co., Ltd.
Address: No. 58, Gaofan Section, Baitang Downline, Wucheng District, Jinhua City, Zhejiang Province
Tel: 0579-82661998 (Consultation) 0579-82131973 (Sales)
Fax Number: 0579-82661998 Postal Code: 321075
Website: www.zjjfyy.com.cn

More information

The company fully deploys 2018 work

On January 27, the group company held a business analysis meeting to review and summarize the work in 2017, arrange and deploy the work for the new year, and put forward work requirements. At the meeting, various professional companies and directly affiliated enterprises reported on the overall work situation in 2017, focusing on analyzing the existing problems and deficiencies, and proposing corresponding solutions and work plans for 2018. Xiang Chongping, deputy general manager of the group company, systematically combed the current human resources efficiency and human resources development of the company. Chen Tianci, chairman of the board of supervisors, made a report and analysis on the "three reductions and three improvements" and the safety and environmental protection work in 2017. Lan Xiaolong, head of finance, analyzed the risks and challenges currently faced by the company according to the operating data and financial situation of its subordinate enterprises. The functional departments and offices of the headquarters also made a brief report on their annual work. Yu Jianhong, general manager of the group company, made a comprehensive review of the company's operation in 2017, compared and analyzed the main economic indicators of various industrial sectors, and pointed out that looking for new investment and development projects around strategic objectives, promoting the optimization of organizational structure and post setting, significantly improving the level of information management, improving the ability of fund management and tax planning, achieving certain results in scientific and technological innovation and technological transformation, and strengthening marketing management and market expansion, safety and environmental protection work is basically up to standard, training and talent development have achieved new results and other work highlights; at the same time, it summarizes and reflects on the shortcomings in strategic decision-making, management innovation, performance appraisal, market operation, and talent team building. After analyzing the current macroeconomic situation and the future trends of various related industries, Yu Jianhong informed

2020

07-31

Peak Pharmaceutical Invests in Shanghai North Carolina to Build API R & D and Production Base

News from our newspaper On January 19, the group company held the second meeting of the tenth board of directors and reviewed and approved the "Proposal on Foreign Investment of Subsidiary Jianfeng Pharmaceutical." On the same day, Jianfeng Pharmaceutical signed an agreement to invest in Shanghai North Carolina Pharmaceutical Technology Co., Ltd. (hereinafter referred to as "Shanghai North Carolina") by acquiring shares and increasing capital. Shanghai Beika is a high-tech enterprise in Shanghai. It has an academician expert workstation and a number of Shanghai high-tech achievements transformation projects. It has won the title of "second prize for scientific and technological progress" in Songjiang District, Shanghai, "patent pilot enterprise" and "enterprise technology center" in Songjiang District, Shanghai. The company has strong research and development capabilities and has obtained 14 patents. At present, its main business is to provide products and customized services for domestic and foreign pharmaceutical companies. The products mainly include Tinib, alkaloids, carbohydrates and other anti-tumor drug intermediates. The customized services are mainly CDMO (contract development and manufacturing) of new drugs and intermediates. Shanghai North Carolina has two wholly-owned subsidiaries, Anhui Changtai Chemical Co., Ltd. (hereinafter referred to as "Changtai Chemical") and Anhui North Carolina Pharmaceutical Co., Ltd. (hereinafter referred to as "Anhui North Carolina"). Changtai Chemical is a pesticide manufacturer designated by the Ministry of Industry and Information Technology. It was established in July 2007. It now has three chemical synthesis workshops and a pesticide preparation compounding workshop, with 10 product approvals and 13 patents. Anhui North Carolina was established in December 2016. Its business scope includes the customization, production and sales of chemical raw materials and pharmaceutical intermediates, and the wholesale and retail of chemical raw materials and products (except hazardous chemicals

2020

07-30

Peak Pharmaceutical Invests in Shanghai North Carolina to Build API R & D and Production Base

2020

07-31

Jianfeng Pharmaceutical was rated as a provincial trademark brand demonstration enterprise

On December 28, 2017, Zhejiang Administration for Industry and Commerce announced the list of trademark brand demonstration counties (cities, districts), demonstration towns (streets) and demonstration enterprises in Zhejiang Province in 2017. Jianfeng Pharmaceutical Company was identified as a trademark brand demonstration enterprise, and it was also the only enterprise in Jinhua City to enter the list. Peak Pharmaceutical was established in 1998 and obtained the first registered trademark in 1999. Since then, Jianfeng Pharmaceutical has been actively carrying out brand building in accordance with the requirements of the Trademark Law and other laws and regulations, and has set up an intellectual property department to carry out trademark management, rights protection and other activities; it has established a sound trademark management system, strictly in accordance with the provisions of the Trademark Law to supervise and manage the use of trademarks inside and outside the enterprise, and safeguard the legitimate rights and interests of the enterprise. Establish strategic cooperation with professional institutions, for trademark applications, renewals and other work. In recent years, Jianfeng Pharmaceutical has also explored trademark investment, creating value through intangible assets such as trademarks and brands, promoting efficiency improvement, and further expanding corporate influence; at the same time, it has continuously increased investment in new product research and development and technological transformation, and actively Declare various patents to provide strong support for brand building with technological innovation. According to incomplete statistics, Jianfeng Pharmaceutical and its subsidiaries currently have more than 120 valid trademarks, including 1 well-known trademark in China, 2 well-known trademarks in Zhejiang Province, 5 well-known trademarks in Jinhua City, and 2 overseas registered trademarks; Obtained more than 40 domestic and international patents. Trademark is an important part of intellectual property rights, in the knowledge economy, brand effect is increasingly becoming the leading force of economic development.

2020

07-31

Peak Pharmaceutical Invests in Shanghai North Carolina to Build API R & D and Production Base

2020

07-31

The company was rated as an advanced unit of the city's focus on talent and love talent.

News from our newspaper On December 11, the Talent Work Leading Group of the Jinhua Municipal Committee of the Communist Party of China commended the advanced units of Jinhua City that value talents and love talents. 36 units including Jianfeng Group won this honor. The selection of advanced units that value talents and love talents is a measure taken by the Jinhua Municipal Party Committee to further create a good atmosphere of focusing on talents and loving talents, fully respect and make good use of the first resource of talents, serve innovation to drive development, and implement the development strategy of strengthening the province with talents and innovation. The enterprises and institutions that have won this honorary title have always regarded talents as the fundamental driving force for development for a long time, regarded the investment of talents as the most effective investment, and integrated the love of talents into the unit culture. Remarkable achievements have been made in gathering talents, achieving talents, transforming and upgrading, and accelerating development. The Jinhua Municipal Party Committee requires the majority of employers to learn from advanced units, vigorously promote the trend of focusing on talents and loving talents, remove the obstacles to the talent development system and mechanism, and in accordance with the requirements of "walking in the forefront and jointly building Jinhua", in order to promote the construction of a modern metropolitan area and accelerate the construction of the province An important growth pole for high-quality development provides talent support and intellectual guarantee. (this newspaper reporter)

2020

07-31

< 1...38 39 40...61 > 跳转到页